Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Legionella, Mycoplasma and other atypical pneumonia

Infectious diseases, microbiology and sexual health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Resuscitate severe hypoxaemia, shock, encephalopathy or rapidly progressive multisystem pneumonia immediately. In England, suspected Legionnaires' disease is an urgent notifiable disease: telephone the local UKHSA health-protection team within 24 hours and report through the statutory service without awaiting laboratory confirmation.

Synopsis

Differentiate exposure-linked intracellular pneumonias by organism, test limitations and public-health consequence, then choose a severity-appropriate intracellular-active regimen without treating a nonspecific 'atypical' phenotype as a diagnosis.

  • The clinically useful group includes Legionella species, Mycoplasma pneumoniae, Chlamydia psittaci and Coxiella burnetii, but ordinary bacteria and respiratory viruses can produce the same radiological pattern.
  • Translate exposure into a dated hypothesis: water aerosols, hotels, spas or healthcare plumbing for Legionella; birds and dried droppings for psittacosis; ruminants and birth products for Q fever; close-contact outbreaks for Mycoplasma.
  • Diarrhoea, confusion, hyponatraemia or liver and renal abnormalities increase suspicion for Legionella but cannot confirm it or justify excluding competing emergencies.
  • Legionella urinary antigen is rapid yet principally detects L pneumophila serogroup 1; obtain lower-respiratory PCR and culture in severe, antigen-negative high-probability or epidemiologically important disease.
  • A beta-lactam alone has no reliable activity for these intracellular or cell-wall-deficient pathogens; add or select an intracellular-active agent when probability and severity warrant it.
  • Use current CAP guidance for the empirical phase, then revise agent and duration with microbiology once the organism, host, pregnancy status and complications are known.
  • Fluoroquinolones are restricted because disabling and potentially irreversible adverse effects occur; use them only when common recommended alternatives are inappropriate and document the reason.
  • Legionnaires' disease requires urgent public-health notification in England, while suspected zoonotic clusters or occupational hazards should be discussed promptly even when the individual disease is not routinely notifiable.

Key red flags

Water-associated Legionella

Severe pneumonia follows hotel, spa, cooling, healthcare or domestic water-aerosol exposure and may include gastrointestinal symptoms, confusion, low sodium or organ injury.

Bird-associated psittacosis

High fever, headache and pneumonia after aviary, poultry, pigeon or veterinary exposure can progress to respiratory failure, hepatitis, myocarditis or encephalopathy.

Severe pathogen-unknown CAP

Shock, profound hypoxaemia, multilobar change or organ failure requires prompt broad CAP treatment including credible intracellular pathogens before exposure testing is complete.

Investigation priorities

01
Dated environmental and animal exposure recordFirst step

Separate plausible sources and supply actionable information for reference testing or public-health investigation.

Management branches

First assessmentConvert exposure into testable probabilities

Pneumonia has epidemiology or extrapulmonary features suggesting an intracellular pathogen.

  1. Stabilise ABCDE, grade CAP severity and take routine cultures and imaging without postponing time-critical treatment.
  2. Build a date-and-place exposure timeline and contact microbiology early for respiratory, reference or paired specimens.
  3. Start the current severity-based CAP regimen with intracellular activity when the probability is clinically material; document pregnancy, QT, renal and interaction constraints.

Key medicines

ClarithromycinFor adult CAP give 500 mg orally or intravenously twice daily for 5 days; specialist-confirmed complicated infection may need longer.Check QTc, potassium and magnesium, hepatic function and renal dose requirements. Review strong CYP3A4 interactions; simvastatin or lovastatin and several antiarrhythmics are incompatible, and pregnancy requires an alternative plan where appropriate.
Levofloxacin when common alternatives are inappropriateFor high-severity adult CAP, NICE lists 500 mg orally or intravenously twice daily for 5 days, then review.Use only after documenting why recommended alternatives are inappropriate. Reduce in renal impairment; avoid in pregnancy, previous serious quinolone reaction and concurrent corticosteroid where possible, and counsel about tendon, neuropathy, CNS, QT and aortic or valvular risks.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG250 pneumonia recommendationsSeverity-based CAP regimens, Legionella testing and antimicrobial review.
  • UKHSA Legionnaires disease guidance and analysisClinical definitions, notification, surveillance and environmental investigation.
  • UKHSA notifiable diseases reporting guidanceCurrent England urgency classification and legal reporting timeframes.
  • UKHSA psittacosis guidanceBird exposure, clinical disease and health-protection context.
  • UKHSA Q fever guidanceRuminant exposure, clinical spectrum and persistent-disease risk.
  • MHRA fluoroquinolone restrictionsCurrent restriction and serious class adverse-effect advice.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom